Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers

Trial Profile

Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2019

At a glance

  • Drugs Aramchol (Primary) ; Atorvastatin; Midazolam
  • Indications Cholelithiasis; Lipodystrophy; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Pharmacokinetics
  • Sponsors Galmed Pharmaceuticals
  • Most Recent Events

    • 07 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top